Pharmaceutical

Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda

Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.

Jan 29, 2024 - 18:00
Pfizer and Astellas seek updated EMA approval for Padcev with Keytruda
Results from a Phase III trial indicated that adding MSD’s blockbuster drug boosted survival rates in advanced bladder cancer patients.
Read the original article

Tags:

Previous Article

Moderna leads the development of mRNA vaccines in infectious diseases

Next Article

Merck is on the lookout for more opportunities within immunology

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT+: Vertex pain drug results met with measured optim...

Jan 30, 2024

Pembrolizumab by Merck for Sezary Syndrome: Likelihood ...

Nov 16, 2023

How hybrid models and tech are shaping the future of clinical research 

How hybrid models and tech are shaping the future of cl...

Nov 3, 2024